orbofiban has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso Castillejos, N; García Iglesias, R; Inglada-Galiana, L; Martín Gil, FJ; San Miguel Hernández, A | 1 |
| Asai, F; Naganuma, H; Ogawa, T; Sugidachi, A | 1 |
2 other study(ies) available for orbofiban and Disease Models, Animal
| Article | Year |
|---|---|
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherosclerosis; Biomarkers; Cardiovascular Diseases; CD40 Ligand; Chromosomes, Human, X; Clinical Trials as Topic; Disease Models, Animal; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Mice; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Pyrrolidines; Risk Factors; Thrombosis | 2007 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspirin; beta-Alanine; Bleeding Time; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Guinea Pigs; Hemostasis; Hypercholesterolemia; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Urea | 2000 |